A randomised placebo-controlled crossover trial of micronised resveratrol as a treatment for Friedreich ataxia

微粉化白藜芦醇治疗弗里德赖希共济失调的随机安慰剂对照交叉试验

• 批准号: nhmrc : GNT1102207
• 负责人: A/Pr John O'Sullivan
• 金额: $ 55.63万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-placebo-controlled-friedreich-ataxia/1346201
• 关键词: randomised; placebo; controlled; crossover; trial

Friedreich ataxia (FRDA) is the most common inherited cause of ataxia (incoordination). There are currently no treatments proven to slow or reverse its inexorable progression. We have shown that resveratrol holds promise as a treatment in an open-label study and now propose a placebo controlled study that will provide evidence of whether resveratrol can slow or reverse symptoms in this devastating disorder.

弗里德赖希共济失调（FRDA）是共济失调（不协调）最常见的遗传原因。目前还没有任何治疗方法被证明可以减缓或逆转其不可阻挡的进展。我们已经在一项开放标签研究中证明了白藜芦醇作为一种治疗方法的前景，现在提出了一项安慰剂对照研究，该研究将提供白藜芦醇是否可以减缓或逆转这种毁灭性疾病的症状的证据。